Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection
Table 3
Differences in median of anti-HBc among different pathological grades and stages and between HBeAg-positive and HBeAg-negative patients.
HBeAg-positive (n = 254)
HBeAg-negative (n = 237)
Z
n
Anti-HBc, median (IQR)
n
Anti-HBc, median (IQR)
Grade
G1
153
3.399 (2.849–3.669)ab
182
4.104 (3.598–4.557)cd
9.442
<0.0001
G2
85
3.643 (3.383–4.011)a
39
4.413 (4.125–4.829)c
6.213
<0.0001
G3
16
3.789 (3.478–3.948)b
16
4.885 (4.100–>5.000)d
3.138
0.0017
χ2
24.785
χ2
17.305
<0.0001
0.0002
Stage
S1
115
3.403 (2.624–3.697)ef
140
4.160 (3.593–4.576)
8.184
<0.0001
S2
89
3.491 (3.265–3.731)g
47
4.116 (3.683–4.612)
5.226
<0.0001
S3
16
3.801 (3.347–4.039)e
16
4.308 (3.849–4.559)
2.864
0.0042
S4
34
3.785 (3.511–4.060)fg
34
4.378 (4.034–>5.000)
4.272
<0.0001
χ2
19.822
χ2
6.886
0.0002
0.0756
IQR, interquartile range. #Comparison among different grades and stages, Kruskal–Wallis test. Comparison between HBeAg-positive and HBeAg-negative patients, Mann–Whitney U test. a–gPairwise comparisons between different grades and stages, , by post hoc analysis.